No abstract available.
Axilla ; Poroma*

No abstract available.
Hyperpigmentation ; Paget Disease, Extramammary* ; Scrotum*

Fibrous hamartoma of infancy (FHI) is a rare benign lesion occurring in the first 2 years of life, particularly in males. Most lesions present as a painless subcutaneous mass. Although the lesion is not distinctive clinically, it has a characteristic microscopic appearance. The lesion histologically consists of three different tissue elements: disorderly collagenous fibrous tissue, myxoid mesenchymal tissue and islands of mature adipocytes. A few cases have overlying skin changes, including alteration in pigmentation, eccrine gland hyperplasia, and increased hair. A 6-month-old male infant had a 6x4 cm sized asymptomatic mass on the right lower back. Multiple coarse hairs were present on the surface. Histopathologic findings showed the typical features of FHI, that is well defined intersecting fibrous trabeculae, small immature cells within loosely textured areas, and mature adipose areas in the lower dermis and subcutaneous layer. Immunohistochemically, vimentin was present in both the trabecular and loosely textured areas, but desmin was not present in any of the components. We report a case of FHI on the right lower back with overlying hypertrichosis in a 6-month-old male patient.
Adipocytes ; Collagen ; Dermis ; Desmin ; Eccrine Glands ; Hair ; Hamartoma ; Humans ; Hyperplasia ; Hypertrichosis ; Infant ; Islands ; Male ; Pigmentation ; Skin ; Vimentin

Radiogenomics or imaging genomics is a novel omics strategy of associating imaging data with genetic information, which has the potential to advance personalized medicine. Imaging features extracted from PET or PET/CT enable assessment of in vivo functional and physiological activity and provide comprehensive tumor information non-invasively. However, PET features are considered secondary to features on conventional imaging, and there has not yet been a review of the radiogenomic approach using PET features. This review article summarizes the current state of PET-based radiogenomic research for cancer, which discusses some of its limitations and directions for future study.

No abstract available.
Lupus Erythematosus, Systemic* ; Sarcoidosis* ; Thyroiditis, Autoimmune

PURPOSE: The present study was designed to examine the distribution of dorsal root ganglion(DRG) cells innervating the anterior and posterior cruciate ligaments of the Sprague-Dawley rat knee joint. MATERIALS AND METHODS: Fluoro-gold(FG) was used to identify the distribution of DRG cells innervating the ligaments, and horseradish peroxidase(HRP) was used to measure the DRG cell size innervating the ligaments. RESULTS: Neural tracers-labelled DRG cells were found ipsilaterally only in the lumbosacra1 DRGs. FG-labelled DRG cells innervating the anterior and posterior cruciate ligaments were found from the 1st lumbar DRG to the 1st sacral DOR(L1-Sl). The majority of FG-labelled DRG cells innervating the poste-rior cruciate ligaments were located in the L4, and the majority innervating the anterior cruciate ligaments were found in the L3, The size of HRP-labelled DRG cells innervating the cruciate ligaments was below 800 micromiter (c), showing that these cells were small. CONCLUSION: This study indicates that the DRG origin of sensory nerves is different in each cruciate ligament of the knee joint. But the size and the type innervating each ligament is similar.
Animals ; Anterior Cruciate Ligament ; Armoracia ; Cell Size ; Diagnosis-Related Groups ; Horseradish Peroxidase ; Knee Joint* ; Knee* ; Ligaments ; Posterior Cruciate Ligament* ; Rats* ; Rats, Sprague-Dawley ; Spinal Nerve Roots*

No abstract available.
Aluminum* ; Onychomycosis* ; Yttrium*

Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23. A 41-year-old woman with a 17-year history of plaque psoriasis and psoriatic arthritis presented with worsening lesions. The patient had previously been treated with a number of topical and systemic medications and narrow band ultraviolet B. However, none of the treatments consistently controlled her disease. Thus, treatment with ustekinumab 45 mg via subcutaneous injection was initiated. Approximately 7 days after the first treatment, she experienced a flare with generalized pustules in her whole body. The condition was controlled with systemic steroid treatment. The patient was subsequently treated with adalimumab, and improvement in her plaque and pustular lesions was noted. Herein, we report a case of psoriasis that flared up after ustekinumab therapy, which was accompanied by a morphological change from plaque to pustular lesions.
Adalimumab ; Adult ; Arthritis, Psoriatic ; Biological Products ; Female ; Glycogen Storage Disease Type VI ; Humans ; Injections, Subcutaneous ; Interleukin-12 ; Interleukin-23 ; Psoriasis* ; Ustekinumab*

No abstract available.
Neck* ; Thyroid Gland* ; Thyroid Neoplasms*

No abstract available.
Humans ; Porokeratosis* ; Vitiligo*